Home > Insider Trading > Filing (0001209191-11-043220)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1338042	Aegerion Pharmaceuticals Inc.	AEGR	Pharmaceutical Preparations (2834)	202960116

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198321	Farah Champsi	One Embarcadero Center Suite 4050 San Francisco CA 94132	No	No	Yes	No
1198332	Edward Penhoet	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1211840	Edward Hurwitz	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1257444	Alta Biopharma Partners Iii Lp	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280234	Alta Biopharma Management Iii Llc	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280238	Alta Embarcadero Biopharma Partners Iii Llc	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No
1280265	Alta Biopharma Partners Iii Gmbh & Co Beteiligungs Kg	One Embarcadero Center Suite 3700 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-08-08	3,847	$12.43	2,459,014	No	4	P	Direct
Common Stock	Acquisiton	2011-08-09	5,038	$12.45	2,464,052	No	4	P	Direct
Common Stock	Acquisiton	2011-08-08	258	$12.43	165,140	No	4	P	Direct
Common Stock	Acquisiton	2011-08-09	338	$12.45	165,478	No	4	P	Direct
Common Stock	Acquisiton	2011-08-08	95	$12.43	60,597	No	4	P	Direct
Common Stock	Acquisiton	2011-08-09	124	$12.45	60,721	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership
Common Stock	2,455,167	Direct
Common Stock	164,882	Direct
Common Stock	60,502	Direct

Footnotes

These securities are beneficially own by Alta BioPharma Partners III, L.P. ("ABPIII").
Alta BioPharma Management III, LLC ("ABMIII") is the general Partner of ABPIII, the managing limited partner of Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("ABPIIIKG"). Farah Champsi, Edward Penhoet, and Edward Hurwitz are directors of ABMIII and managers of Alta Embarcadero BioPharma Partners III, LLC ("AEBPIII"), along with ABPIII and ABPIIIKG shall be known as "the Funds," exercise shared voting and investment power with respect to the securities held by the funds. Alison Kiley, a director of the Issuer, is a member of ABMIII. She does not have sole or shared voting power over the shares owned by ABPIII, ABPIIIKG, and AEBPIII. Each of the reporting persons disclaim beneficial ownership of such securities, except to the extend of his, her, or its proportionate pecuniary interest herein.
On August 8, 2011, ABPIII, ABMPIIIKG, and AEBPIII acquired 3847, 258, and 95 shares of the Issuer's Common Stock, respectively, from the public market at an average price of $12.4296 per share.
On August 9, 2011, ABPIII, ABMPIIIKG, and AEBPIII acquired 5038, 338, and 124 shares of the Issuer's Common Stock, respectively, from the public market at an average price of $12.454 per share.
These securities are beneficially own by ABPIIIKG.
These securities are beneficially own by AEBPIII.